diacerein 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 849 | 13739-02-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase
|
Drug dosage:
None
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Brain scan abnormal | 146.50 | 64.89 | 21 | 388 | 1147 | 64497176 |
| Cerebral artery thrombosis | 140.49 | 64.89 | 20 | 389 | 1039 | 64497284 |
| Areflexia | 115.96 | 64.89 | 21 | 388 | 4986 | 64493337 |
| Hemiplegia | 85.23 | 64.89 | 19 | 390 | 12749 | 64485574 |
| Ischaemic stroke | 84.01 | 64.89 | 22 | 387 | 29013 | 64469310 |
| Facial paralysis | 77.75 | 64.89 | 19 | 390 | 18947 | 64479376 |
| Disease recurrence | 77.49 | 64.89 | 21 | 388 | 31489 | 64466834 |
| Respiratory distress | 71.19 | 64.89 | 22 | 387 | 52309 | 64446014 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AX21 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Other antiinflammatory and antirheumatic agents, non-steroids |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.67 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Caspase-3 | Enzyme | EC50 | 5.10 | CHEMBL | |||||
| Caspase-7 | Enzyme | EC50 | 4.83 | CHEMBL | |||||
| N-acylethanolamine-hydrolyzing acid amidase | Enzyme | IC50 | 6.16 | CHEMBL | |||||
| Female germline-specific tumor suppressor gld-1 | Unclassified | IC50 | 5.14 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07270 | KEGG_DRUG |
| 22759 | RXNORM |
| C0057678 | UMLSCUI |
| CHEBI:94708 | CHEBI |
| CHEMBL41286 | ChEMBL_ID |
| DB11994 | DRUGBANK_ID |
| C025292 | MESH_SUPPLEMENTAL_RECORD_UI |
| 26248 | PUBCHEM_CID |
| 10800 | IUPHAR_LIGAND_ID |
| 5371 | INN_ID |
| 4HU6J11EL5 | UNII |
| 005800 | NDDF |
| 702835000 | SNOMEDCT_US |
| 714674003 | SNOMEDCT_US |
Pharmaceutical products:
None